Topic Code
HORIZON-HLTH-2026-01-DISEASE-04
F&T Portal
Call Identifier
HORIZON-HLTH-2026-01
Call 01 — single stage (2026)
Instrument
HORIZON-RIA
Research and Innovation Action
Budget Model
Actual Costs
Standard MGA
Funding Rate
100%
Annex G — RIA = 100%
Page Limit (Part B)
40 pages
RIA + actual costs (Annex A)
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — topic override
Expected Projects
5
€9–11M per project (WP stated)
Destination
Tackling diseases and reducing disease burden
WP Part 4
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Excluded ⚠
Destination excludes RIA/IA
Special Conditions
Portfolio by virus ⚠
Balanced across targeted viruses
Chinese entities are excluded from RIA actions under this destination. Legal entities established in China are not eligible to participate in Research and Innovation Actions (RIAs) falling under Destination ‘Tackling diseases and reducing disease burden’.
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
Portfolio approach: Grants will be awarded to ensure balanced coverage across the targeted viruses (Junin, Lassa, Andes, Hantaan, Sin Nombre, Hendra, Enterovirus D68, Venezuelan equine encephalitis virus), not solely by ranking.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Mandatory annex: Proposals under this topic are expected to include clinical studies. Applicants should provide details in the dedicated annex using the template provided in the submission system.
Expected Outcomes
- The scientific and clinical communities have a better understanding of and access to experimental vaccines for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation, including better understanding of biological sex and social determinants that influence immune response, vaccine efficacy, safety, and uptake.
- Candidate vaccines are available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day